This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

This study has been terminated.
Information provided by (Responsible Party):
Astex Pharmaceuticals Identifier:
First received: June 6, 2005
Last updated: January 22, 2013
Last verified: October 2009
Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug combination will also be evaluated.

Condition Intervention Phase
Pancreatic Cancer Drug: Rubitecan Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy

Resource links provided by NLM:

Further study details as provided by Astex Pharmaceuticals:

Primary Outcome Measures:
  • survival

Enrollment: 39
Study Start Date: February 2005
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient is at least 18 years of age.
  • The patient has histologically or cytologically confirmed, non-resectable, Stage II-IV primary adenocarcinoma of the pancreas.
  • The patient has had a baseline computed tomography (CT) scan, or magnetic resonance imaging (MRI), to evaluate tumor(s) within 28 days prior to randomization.
  • The patient has never been treated with prior chemotherapy, with the exception of low-dose 5-fluorouracil (5-FU) as a radiation sensitizer.
  • The patient has sufficiently recovered from the effects of previous surgery (no less than 3 weeks prior to randomization), radiotherapy, and/or immunotherapy (no less than 4 weeks prior to randomization).
  • The patient's estimated life expectancy is at least 12 weeks.
  • The patient has a Karnofsky Performance Status between 50 and 100.
  • The patient has adequate bone marrow function.
  • The patient has adequate hepatic and renal function.

Exclusion Criteria:

  • The patient has any active, uncontrolled infection requiring antibiotics.
  • The patient has any serious, uncontrolled concomitant systemic disorder.
  • The patient has surgery scheduled within 8 weeks following initiation of treatment.
  • The patient is pregnant or nursing.
  • The patient is not capable of consistent oral intake of at least 3 L/day of fluid and/or requires constant intravenous (IV) hydration or frequent tube feeding.
  • The patient is receiving any investigational agent(s) or has been a participant in a clinical trial within the last 30 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00113256

United States, California
Compassionate Cancer Care Medical Group
Corona, California, United States, 92882
11100 Warner Avenue, Ste. 200
Fountain Valley, California, United States, 92708
The Cancer Research & Prevention Center
Soquel, California, United States, 95073
United States, Colorado
Mile High Oncology
Denver, Colorado, United States, 80210
United States, Kentucky
Norton Healthcare, Inc.
Louisville, Kentucky, United States, 40202
United States, Louisiana
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States, 70809
Medical Oncology
Baton Rouge, Louisiana, United States, 70809
United States, Mississippi
N. Mississippi Hematology & Oncology Associates
Tupelo, Mississippi, United States, 38801
United States, Missouri
Kansas City Cancer Center
Kansas City, Missouri, United States, 64111
United States, New York
Cancer Research of Long Island
Great Neck, New York, United States, 11023
United States, South Carolina
Charleston Hematology Oncology, PA
Charleston, South Carolina, United States, 29403
Sponsors and Collaborators
Astex Pharmaceuticals
  More Information

Responsible Party: Astex Pharmaceuticals Identifier: NCT00113256     History of Changes
Other Study ID Numbers: SGI-RUB-048
Study First Received: June 6, 2005
Last Updated: January 22, 2013

Keywords provided by Astex Pharmaceuticals:
pancreatic cancer
RFS 2000

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors processed this record on August 18, 2017